|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1995-4-7
|
|
pubmed:abstractText |
Paclitaxel (Taxol; Bristol-Myers Squibb Co, Princeton, NJ) is a novel antimicrotubule agent with anti-tumor activity against ovarian and breast carcinomas. Its activity when administered as a 3-hour intravenous infusion in patients with relapsed non-Hodgkin's lymphoma (NHL) has not been studied.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
583-7
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:7884419-Adult,
pubmed-meshheading:7884419-Aged,
pubmed-meshheading:7884419-Alopecia,
pubmed-meshheading:7884419-Drug Administration Schedule,
pubmed-meshheading:7884419-Female,
pubmed-meshheading:7884419-Humans,
pubmed-meshheading:7884419-Lymphoma, Non-Hodgkin,
pubmed-meshheading:7884419-Male,
pubmed-meshheading:7884419-Middle Aged,
pubmed-meshheading:7884419-Paclitaxel,
pubmed-meshheading:7884419-Peripheral Nervous System Diseases,
pubmed-meshheading:7884419-Recurrence,
pubmed-meshheading:7884419-Remission Induction
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
